Otherwise, it should be kept in mind that hepatic AMPK activity could be unimpaired or even upregulated in early NAFLD disease and effects of pharmacological stimulation could therefore depend on disease stage. Here, PRKAA1 is linked to metabolic dysfunction-associated steatotic liver disease.